Canaccord Genuity Reiterates a 'Buy' on DexCom (DXCM); Management Shines Light on '12 Catalysts
Tweet Send to a FriendGet Alerts DXCM Hot Sheet
Price: $21.18 +8.89%
Rating Summary:
8 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
8 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade DXCM Now!
Canaccord Genuity reiterates a 'Buy' on DexCom (NASDAQ: DXCM) price target of $14.00 (from $11.50).
Analyst, William J. Plovanic, said, "We recently traveled with management from DexCom and came away with more clarity regarding 2012 catalysts, the US regulatory status of the Gen4 sensor, partner projects, and the longer-term new product pipeline...Commentary related to the regulatory status of its Gen4 sensor continues to be very encouraging. Given certain regulatory tasks/milestones that have already been completed, we believe that approval by YE12 is a very real possibility...Management has a stretch goal of reaching cash flow positive at YE12/early 2013 vs. our mid-2013 view."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $12.63 yesterday, with a 52 week range of $6.75-$15.77.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, William J. Plovanic, said, "We recently traveled with management from DexCom and came away with more clarity regarding 2012 catalysts, the US regulatory status of the Gen4 sensor, partner projects, and the longer-term new product pipeline...Commentary related to the regulatory status of its Gen4 sensor continues to be very encouraging. Given certain regulatory tasks/milestones that have already been completed, we believe that approval by YE12 is a very real possibility...Management has a stretch goal of reaching cash flow positive at YE12/early 2013 vs. our mid-2013 view."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $12.63 yesterday, with a 52 week range of $6.75-$15.77.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform
- Lazard Cuts PT on Aruba (ARUN) to $18; Cisco Pressure Lingers, But Fundamentals Solid
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
